Drug profile · INN
lazertinib mesylate
LAZCLUZE
lazertinib mesylate (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lazertinib mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lazertinib mesylate (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lazertinib mesylate?
lazertinib mesylate (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lazertinib mesylate?
LAZCLUZE is a marketed brand name for lazertinib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lazertinib mesylate?
lazertinib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.